ANIK at a glance
Anika Therapeutics, Inc. (ANIK, SEC CIK 898437) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on July 29, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Anika Therapeutics, Inc. (ANIK) reported revenue of $112.8 million (down 5.9% from FY2024) and a net loss of $10.9 million. Diluted EPS was -$0.76.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Anika Therapeutics, Inc. (ANIK) shares worth $82.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Fischetti Gary P on August 4, 2026 of 1,000 shares at $20.32 per share.
- In the last 90 days, ANIK insiders reported 2 open-market purchases ($41K) and 0 open-market sales ($0) on Form 4, a net purchase of $41K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $112.8M
- −5.9% vs prior year
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$41K
- 13F holders
- 24 funds
- $82.6M · +1 vs prior quarter
- Latest 8-K
- Jul 29, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $32.6M, up $4.4M or 16% YoY
- Gross margin 65% vs 51% YoY, driven by volume, production, and sales mix
- OEM channel $18.7M, up 14%; Commercial channel $13.9M, up 17%
- Cash $38.4M vs $57.5M at December 31, 2025; operating cash flow used $5.5M
- Cingal NDA timing remains subject to CMC and regulatory requirements; Hyalofast PMA review ongoing after January 2026 deficiency letter
Risk Factors
- Risk Factors section not provided; filing excerpt covers Items 2–6 only
- No basis to identify newly added or materially updated risks versus the 10-K
- No regulatory, legal, compliance, operational, competitive, market, or financial risk factors disclosed in provided text
AI summary of the ANIK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results
Item 1.01: Entry into a Material Definitive Agreement
- $50.0M senior revolving credit facility extended through July 10, 2031
- Potential $50.0M expansion, bringing maximum commitments to $100.0M subject to lender approval
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board-approved amendment and restatement of Anika’s 2017 Omnibus Incentive Plan
- Revised Seventh Amended Plan subject to stockholder approval at the 2026 Annual Meeting
Item 5.07: Submission of Matters to a Vote of Security Holders
- 84.14% voting participation, with 11,195,667 of 13,305,624 eligible shares represented
- All three Class III nominees elected through 2029; John Henneman received 536,988 against votes
AI summaries of ANIK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ANIK
Don't miss the next ANIK filing
- Alerts as it files. A push when ANIK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ANIK, by share count.
- Ask anything. An AI agent that reads every ANIK filing and answers with sources.
ANIK alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fischetti Gary P | Buy | Aug 4, 2026 | 1,000 | $20.32 |
| Fischetti Gary P | Buy | Aug 3, 2026 | 1,000 | $20.75 |
| Fischetti Gary P | A | Jun 18, 2026 | 10,402 | - |
| CONLEY SHERYL L | A | Jun 18, 2026 | 10,402 | - |
| HENNEMAN JOHN B III | A | Jun 18, 2026 | 10,402 | - |
| Richard Stephen | A | Jun 18, 2026 | 10,402 | - |
| Capper Joseph H | A | Jun 18, 2026 | 10,402 | - |
| Griffin Stephen D. | F | Jun 3, 2026 | 3,769 | $14.41 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $119.9M | $112.8M |
| Gross Profit | - | $76.0M | $63.8M |
| Operating Income | - | -$5.1M | -$11.1M |
| Net Income | - | -$56.4M | -$10.9M |
| Gross Margin | - | 63.4% | 56.6% |
| Op. Margin | - | -4.3% | -9.8% |
| Net Margin | - | -47.0% | -9.6% |
| Balance Sheet | |||
| Total Assets | $270.6M | $202.7M | $190.3M |
| Equity | $212.3M | $154.0M | $143.5M |
| ROE | - | -36.6% | -7.6% |
| Per Share | |||
| EPS | - | $-3.83 | $-0.76 |
| Cash Flow | |||
| Operating CF | - | $5.4M | $11.2M |
| CapEx | - | $7.7M | $6.8M |
Source: XBRL data in Anika Therapeutics, Inc. (ANIK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ANIK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $82.6M |
| Q1 2026 | 23 | $84.3M |
| Q4 2025 | 22 | $55.5M |
| Q3 2025 | 22 | $48.8M |
| Q2 2025 | 23 | $48.5M |
| Q1 2025 | 20 | $46.5M |
| Q4 2024 | 16 | $46.3M |
| Q3 2024 | 16 | $55.3M |
- AQR Capital Management+287.6K (+106%)
- JPMorgan Chase & Co+19.9K (+58%)
- Goldman Sachs Group+19.8K (+9%)
- Two Sigma Investments+16.8K (+7%)
- D.E. Shaw & Co+15.3K (+7%)
- Morgan Stanley−257.7K (-30%)
- BlackRock−145.2K (-9%)
- State Street Corp−34.2K (-10%)
- Vanguard Capital Management LLC−33.7K (-6%)
- Renaissance Technologies LLC−20.8K (-4%)
- Millennium Management+14.4K
- Prudential Financial+11.3K
- Citadel Advisors LLC−52.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 166 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ANIK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | May 4, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 10-K | Mar 3, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
ANIK SEC filings: frequently asked questions
Are ANIK insiders buying or selling?
In the last 90 days, Anika Therapeutics, Inc. (ANIK) officers, directors and 10% owners reported 2 open-market purchases worth $41,060 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ANIK stock?
As of June 30, 2026, the largest Anika Therapeutics, Inc. (ANIK) holders among the 13F filers tracked by SignalX were BlackRock ($21.2 million), Morgan Stanley ($9.0 million), Vanguard Capital Management LLC ($8.4 million), AQR Capital Management ($8.2 million), Renaissance Technologies LLC ($7.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ANIK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Anika Therapeutics, Inc. (ANIK) reported revenue of $112.8 million (down 5.9% from FY2024) and a net loss of $10.9 million. Diluted EPS was -$0.76. The figures come from the XBRL data in the 10-K.
What did ANIK report in its latest 8-K?
Anika Therapeutics, Inc. (ANIK) filed an 8-K on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026.
What are the latest ANIK SEC filings?
Anika Therapeutics, Inc. (ANIK) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on July 29, 2026, an 8-K current report on July 29, 2026 and a Form 4 insider filing on August 5, 2026.
What is ANIK's SEC CIK number?
Anika Therapeutics, Inc. (ANIK)'s SEC Central Index Key (CIK) is 898437. EDGAR lists every ANIK filing under that number.
Ask anything about ANIK
The research agent reads ANIK's filings, financials, insider trades and 13F holders, then answers with sources.